These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 19397460

  • 1. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
    Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE.
    Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
    [Abstract] [Full Text] [Related]

  • 2. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T, Tuberculosis Trials Consortium.
    Clin Infect Dis; 2005 May 15; 40(10):1481-91. PubMed ID: 15844071
    [Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA, Weiner MH, Burman WJ, Vernon AA, Zhao ZA, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo C, Hsyu PH, Becker MI, Peloquin CA, Tuberculosis Trials Consortium.
    Pharmacotherapy; 2007 Jun 15; 27(6):793-800. PubMed ID: 17542762
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA.
    Clin Infect Dis; 2009 Nov 01; 49(9):1305-11. PubMed ID: 19807276
    [Abstract] [Full Text] [Related]

  • 5. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
    Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, Kenyon TA, Moeti TL, Moffat HJ, Peloquin CA.
    Clin Infect Dis; 2005 Aug 15; 41(4):461-9. PubMed ID: 16028152
    [Abstract] [Full Text] [Related]

  • 6. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J, Munsiff SS, Driver CR, Sackoff J.
    Clin Infect Dis; 2005 Jul 01; 41(1):83-91. PubMed ID: 15937767
    [Abstract] [Full Text] [Related]

  • 7. Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection.
    Ahmed R, Cooper R, Foisy M, Der E, Kunimoto D.
    J Int Assoc Physicians AIDS Care (Chic); 2012 Jul 01; 11(5):273-6. PubMed ID: 22875581
    [Abstract] [Full Text] [Related]

  • 8. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER, Joseph K.
    Clin Infect Dis; 2009 May 15; 48(10):1471-4. PubMed ID: 19368504
    [Abstract] [Full Text] [Related]

  • 9. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2002 Mar 15; 51(10):214-5. PubMed ID: 11922192
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M, Corti N, Müller D, Henning L, Gutteck U, von Braun A, Weber R, Fehr J.
    Swiss Med Wkly; 2015 Mar 15; 145():w14223. PubMed ID: 26700218
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak.
    Spradling P, Drociuk D, McLaughlin S, Lee LM, Peloquin CA, Gallicano K, Pozsik C, Onorato I, Castro KG, Ridzon R.
    Clin Infect Dis; 2002 Nov 01; 35(9):1106-12. PubMed ID: 12384845
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum concentrations of rifampicin and isoniazid in tuberculosis.
    Seth V, Beotra A, Seth SD, Semwal OP, Kabra S, Jain Y, Mukhopadhya S.
    Indian Pediatr; 1993 Sep 01; 30(9):1091-8. PubMed ID: 8125594
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
    Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, Cronin W, Hooper N, Bishai W, Sterling TR.
    Clin Infect Dis; 2004 Mar 01; 38(5):731-6. PubMed ID: 14986259
    [Abstract] [Full Text] [Related]

  • 19. Does AIDS impair the absorption of antituberculosis agents?
    Taylor B, Smith PJ.
    Int J Tuberc Lung Dis; 1998 Aug 01; 2(8):670-5. PubMed ID: 9712282
    [Abstract] [Full Text] [Related]

  • 20. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.
    Matteelli A, Olliaro P, Signorini L, Cadeo G, Scalzini A, Bonazzi L, Caligaris S, Tomasoni L, Tebaldi A, Carosi G.
    Int J Tuberc Lung Dis; 1999 Nov 01; 3(11):1043-6. PubMed ID: 10587327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.